C3N-02142
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 63.41409993
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.430
- INTERFERON_GAMMA_RESPONSE+0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- ALLOGRAFT_REJECTION+0.320
- ANGIOGENESIS+0.310
- APICAL_JUNCTION+0.310
- COMPLEMENT+0.290
- PANCREAS_BETA_CELLS+0.250
- GLYCOLYSIS+0.240
- IL6_JAK_STAT3_SIGNALING+0.190
Top 10 suppressed
- ANDROGEN_RESPONSE-0.300
- UV_RESPONSE_DN-0.260
- MYC_TARGETS_V1-0.220
- E2F_TARGETS-0.110
- OXIDATIVE_PHOSPHORYLATION-0.110
- ESTROGEN_RESPONSE_EARLY-0.090
- BILE_ACID_METABOLISM-0.070
- DNA_REPAIR-0.070
- ESTROGEN_RESPONSE_LATE-0.070
- NOTCH_SIGNALING-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0BZ-01A-31R-A12P-07 | — | C | 0.742 |
| 2 | 20130243.TNBC | — | D | 0.738 |
| 3 | SRR5088821 | — | — | 0.734 |
| 4 | SRR10900548 | — | — | 0.705 |
| 5 | SJEPD034_D.RNA-Seq | EPN | Supratentorial EPN | 0.700 |
| 6 | MNG814 | — | — | 0.695 |
| 7 | MNG390 | — | — | 0.686 |
| 8 | 20050099.TNBC | — | D | 0.685 |
| 9 | SRR8518406 | — | D | 0.684 |
| 10 | TCGA-BH-A0RX-01A-21R-A084-07 | — | D | 0.680 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |